×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Why MacroGenics, Inc.'s (NASDAQ:MGNX) CEO Pay Matters To You
Yahoo News New Zealand
In 2001, Scott Koenig was appointed CEO of MacroGenics, Inc. (NASDAQ:MGNX). First, this article will compare CEO...
9 hours ago
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
GlobeNewswire
ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing,...
2 days ago
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
Bakersfield.com
ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing,...
2 days ago
Gilead, MacroGenics Ink Antibody Licensing Deal
AOL.com
Privately-held biotech firm MacroGenics has signed an agreement with Gilead Sciences to develop and produce Dual-Affinity Re-Targeting...
2 days ago
MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Recommendation of “Moderate Buy” by Analysts
Defense World
Read MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Recommendation of “Moderate Buy” by Analysts at Defense World.
1 day ago
AbbVie ends stay with the ADAM family, dropping MacroGenics-partnered ADC in light of early data
Fierce Biotech
IMGC936 fell short of safety and efficacy expectations in solid tumors, prompting AbbVie and its equal partner MacroGenics to walk away from...
1 month ago
MacroGenics (MGNX) Set to Announce Quarterly Earnings on Thursday
MarketBeat
MacroGenics (NASDAQ:MGNX) will be releasing earnings after the market closes on Thursday, May 9, Zacks reports.
18 hours ago
MacroGenics (MGNX) Q4 2023 Earnings Call Transcript
The Motley Fool
Our net loss was $9.1 million for the year ended December 31, 2023, compared to a net loss of $119.8 million for the year ended December 31,...
1 month ago
MacroGenics stock gains on data for antibody drug conjugate
Seeking Alpha
MacroGenics (MGNX) stock rises after positive interim data from its Phase 2 TAMARACK study for its prostate cancer drug vobra duo.
1 month ago
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
Yahoo Finance
Early interim safety data from Phase 2 TAMARACK study, including comparison to retrospective analysis from Phase 1 study, as submitted in...
1 month ago